Patents by Inventor Michael N. Greco

Michael N. Greco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
    Patent number: 10844045
    Abstract: Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 24, 2020
    Assignee: BETA PHARMA, INC.
    Inventors: Michael N. Greco, Michael J. Costanzo, Michael A. Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • PHARMACEUTICAL SALTS N-(2-(2-(DIMETHYLAMINO)ETHOXY)-4-METHOXY-5-((4-(1-METHYL-1H-INDOL-3-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)ACRYLAMIDE AND CRYSTALLINE FORMS THEREOF
    Publication number: 20190233399
    Abstract: Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: August 1, 2019
    Applicant: Beta Pharma, Inc.
    Inventors: Michael N. Greco, Michael J. Costanzo, Michael A. Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20190031618
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor, more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: October 3, 2018
    Publication date: January 31, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • Benzimidazole derivatives useful as CB-1 inverse agonists
    Patent number: 10118900
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 6, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
    Patent number: 9815790
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: November 14, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • Cinnoline derivatives useful as CB-1 receptor inverse agonists
    Patent number: 9732061
    Abstract: The present invention is directed to cinnoline derivatives pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: August 15, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco, Donald W. Ludovici, Michael H. Parker
  • Indazole derivatives useful as CB-1 inverse agonists
    Patent number: 9682940
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: June 20, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Michael H. Parker, Bart L. DeCorte, Michael N. Greco
  • Quinazoline derivatives useful as CB-1 inverse agonists
    Patent number: 9682955
    Abstract: The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 20, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco
  • BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057929
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057925
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Michael H. Parker, Bart L. DeCorte, Michael N. Greco
  • CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057922
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS
    Publication number: 20160200719
    Abstract: The present invention is directed to cinnoline derivatives pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco, Donald W. Ludovici, Michael H. Parker
  • Quinazoline Derivatives Useful as CB-1 Inverse Agonists
    Publication number: 20160068512
    Abstract: The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 10, 2016
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco
  • Phosphonic acid compounds as inhibitors of serine proteases
    Patent number: 8703957
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: April 22, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Michael J. Hawkins, Eugene Powell
  • Phosphonic acid compounds as inhibitors of serine proteases
    Patent number: 8609888
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: December 17, 2013
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Michael J. Hawkins, Eugene Powell
  • NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
    Publication number: 20130281407
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 24, 2013
    Inventors: Michael N. Greco, Harold R. Almond, Michael J. Hawkins, Eugene Powell
  • Method of treating asthma
    Patent number: 8546358
    Abstract: The present invention is directed to a method for treating or ameliorating asthma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of compound 17:
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 1, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
  • Phosphonic acid compounds as inhibitors of serine proteases
    Patent number: 8497373
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: July 30, 2013
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Lawrence de Garavilla, Michael J. Hawkins, Michael J. Humora, Yun Qian, Donald Gilmore Walker, Sergio Cesco-Cancian, Christopher Norman Nilsen, Mitul N. Patel, Kirk Leonard Sorgi, Eugene Powell
  • ?-ketoamide derivatives useful endothelial lipase inhibitors
    Patent number: 8476302
    Abstract: The present invention is directed to ?-ketoamide derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 2, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael N. Greco, Margery A. Connelly, Shyamali Ghosh, Dennis J. Hlasta, Edward C. Lawson, Eric Strobel, Michele A. Weidner-Wells, Hong Ye
  • Phosphonic acid compounds as inhibitors of serine proteases
    Patent number: 8461195
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 11, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Michael J. Hawkins, Eugene Powell